Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 563Neoplasms 462Carcinoma, Non-Small-Cell Lung 422Prostatic Neoplasms 344Colorectal Neoplasms 325Lung Neoplasms 269Multiple Myeloma 235Neoplasm Metastasis 197Pancreatic Neoplasms 189Leukemia, Myeloid, Acute 187Ovarian Neoplasms 182Melanoma 153Squamous Cell Carcinoma of Head and Neck 143Head and Neck Neoplasms 121Recurrence 119Carcinoma, Renal Cell 119Carcinoma, Hepatocellular 119Stomach Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Glioblastoma 114Endometrial Neoplasms 114Lymphoma 113Brain Neoplasms 111Lymphoma, Non-Hodgkin 108Uterine Cervical Neoplasms 101Triple Negative Breast Neoplasms 99Hematologic Neoplasms 98Urinary Bladder Neoplasms 97Glioma 91Leukemia, Lymphocytic, Chronic, B-Cell 88

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Ascites × 30 days × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡